Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human CEBPA Antibodies:
anti-Mouse (Murine) CEBPA Antibodies:
anti-Rat (Rattus) CEBPA Antibodies:
Go to our pre-filtered search.
Human Monoclonal CEBPA Primary Antibody for FACS, ICC - ABIN269606
Ferrari-Amorotti, Keeshan, Zattoni, Guerzoni, Iotti, Cattelani, Donato, Calabretta: Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha. in Blood 2006
Show all 4 Pubmed References
Cow (Bovine) Polyclonal CEBPA Primary Antibody for IHC, WB - ABIN2787465
Singh, Trivedi, Behre: C/EBPalpha S248A mutation reduces granulocytic differentiation in human leukemic K562 cells. in Biochemical and biophysical research communications 2008
Show all 3 Pubmed References
Human Monoclonal CEBPA Primary Antibody for ICC, FACS - ABIN969048
Jin, Zhang, Yan, Liu, Wang, Ge, Zhai: C/EBPalpha regulates SIRT1 expression during adipogenesis. in Cell research 2010
Human Monoclonal CEBPA Primary Antibody for FACS, ELISA - ABIN969507
Geest, Buitenhuis, Vellenga, Coffer: Ectopic expression of C/EBPalpha and ID1 is sufficient to restore defective neutrophil development in low-risk myelodysplasia. in Haematologica 2009
a MEF2C and CEBPA correlation in CML disease progression
CEBPA gene expression is significantly associated with long-term changes in Blood Pressure, providing a link between gene expression and Blood Pressure.
We provide evidence that CCAAT/enhancer-binding protein alpha directly binds the miR (show MLXIP Antibodies)-203 gene within its hairpin region and thereby induces miR (show MLXIP Antibodies)-203 transcription
High CEBP expression is associated with glioblastomas.
identified high frequencies of mutations in CEBPA (32.7%), GATA2 (show GATA2 Antibodies) (22.4%), NPM1 (show NPM1 Antibodies) (15.5%), SETBP1 (show SETBP1 Antibodies) (12.1%) and U2AF1 (show U2AF1 Antibodies)
our data show that excess p30 (show CENPV Antibodies) cooperated with TRIB2 (show TRIB2 Antibodies) only in the presence of p42 (show EPB42 Antibodies) to accelerate acute myeloid leukaemia (AML (show RUNX1 Antibodies)), and the direct interaction and degradation of C/EBPa p42 (show EPB42 Antibodies) is required for TRIB2 (show TRIB2 Antibodies)-mediated AML (show RUNX1 Antibodies).
A single +42-kb enhancer is essential for CEBPA expression in myeloid cells only.
Co-occurrence of mutations in CSF3R (show CSF3R Antibodies) and CEBPA in a well-defined acute myeloid leukemia (show BCL11A Antibodies) subset, which uniformly responds to JAK (show JAK3 Antibodies) inhibitors; this paves the way to personalized clinical trials for this disease.
we established a reliable and straightforward screening method, based simply on the multidimensional analysis of widely available phenotypic parameters, suitable for large-scale detection of CEBPA-dm status and potentially able to overcome technical issues related to molecular methods.
This study of a large multi-generational pedigree reveals that a germline mutation in the C-terminal bZip domain can alter the ability of C/EBP-alpha to bind DNA and reduces transactivation, leading to acute myeloid leukemia (show BCL11A Antibodies).
results indicate that JMJD2B (show KDM4B Antibodies) regulates PPARgamma (show PPARG Antibodies) and C/EBPalpha during adipogenesis
these data indicate that CycC (show CCNC Antibodies) activates adipogenesis in part by stimulating the transcriptional activity of C/EBPalpha.
Taken together, these findings demonstrate that artesunate inhibits adipogenesis in 3T3-L1 preadipoytes through the reduced expression and/or phosphorylation levels of C/EBP-alpha, PPAR-gamma (show PPARG Antibodies), FAS (show FAS Antibodies), perilipin A (show PLIN1 Antibodies), and STAT-3 (show STAT3 Antibodies).
we show that SIX1 (show SIX1 Antibodies) binds to adipogenic and brown marker genes and interacts with C/EBPa, C/EBPb (show CEBPB Antibodies) and EBF2 (show EBF2 Antibodies), suggesting their functional cooperation during adipogenesis.
these results indicate that C/EBPalpha functions throughout osteoclastogenesis as well as in Osteoclast function. This study provides additional understanding of the roles of C/EBPalpha in Osteoclast biology.
the DNA sequences to which EVI1 (show MECOM Antibodies) binds at +35 and +37 kb and show that mutation of one of these releases Cebpa from EVI1 (show MECOM Antibodies)-induced suppression.
The efficient repression of E2F (show E2F1 Antibodies) dependent S-phase genes and the activation of differentiation genes reside in the balanced DNA binding capacity of C/EBP alpha.
Cebpa enhancers and silencers in a transcriptional model have roles in hematopoietic lineage specification
Data show that CCAAT-enhancer-binding protein-alpha (C/EBPalpha) directly regulates Kruppel-like factor 4 (Klf4 (show KLF4 Antibodies)) expression and increasing the levels of histone demethylase (show MBD2 Antibodies) Lsd1 (show KDM1A Antibodies) and transcription factor Brd4 (show BRD4 Antibodies) in B cell.
C/ebpalpha plays a role in liver growth regulation via the p53 (show TP53 Antibodies) pathway.
Dnmt1 (show DNMT1 Antibodies) is required for hematopoietic stem and progenitor cells maintenance via cebpa regulation during definitive hematopoiesis in zebrafish
Data suggest that upregulation of 10-formyltetrahydrofolate dehydrogenase (FDH (show ALDH1L1 Antibodies)) involving CEBPalpha helps relieve embryonic oxidative stress induced (show SQSTM1 Antibodies) by ethanol exposure.
Bmi1 (show BMI1 Antibodies) acts immediately downstream of CCAAT enhancer binding protein-alpha to regulate the survival and self-renewal of hematopoietic stem cells and contribute to the erythropoietic dysplasia.
Results provide first evidence that sumoylation of Cebp-alpha (via SUMO1 (show SUMO1 Antibodies), SUMO2 (show SUMO2 Antibodies), and SUMO3 (show SUMO3 Antibodies)) might contribute to cell fate decision of myelo-erythroid progenitor cells in intermediate cell mass during primitive [extramedullary] hematopoiesis.
An evolutionarily conserved PTEN (show PTEN Antibodies)-C/EBPalpha-CTNNA1 (show CTNNA1 Antibodies) axis controls myeloid development and transformation.
a C/EBP recognition sequence in the proximal promoter region of C/EBPalpha is essential for IL-6 (show IL6 Antibodies)-mediated repression
These results suggest that the CEBPA gene is a strong candidate gene that affects carcass traits in Qinchuan cattle.
Expressions of C-EBPalpha and myostatin (show MSTN Antibodies) in muscles were higher in the concentrate-fed group than in the grass hay (show GTF2H5 Antibodies)-fed group.
C/EBPalpha is an essential regulatory factor for perilipin5 transcription and suggest that fasting stimulates perilipin5 transcription through influencing C/EBPalpha expression.
The differential expression of specific CEBPA/B isoforms observed in maturing follicles and CL may contribute to changes in follicular cell differentiation and increasing steroidogenic capacity.
The protein encoded by this intronless gene is a bZIP transcription factor which can bind as a homodimer to certain promoters and enhancers. It can also form heterodimers with the related proteins CEBP-beta and CEBP-gamma. The encoded protein has been shown to bind to the promoter and modulate the expression of the gene encoding leptin, a protein that plays an important role in body weight homeostasis. Also, the encoded protein can interact with CDK2 and CDK4, thereby inhibiting these kinases and causing growth arrest in cultured cells.
CCAAT/enhancer-binding protein alpha
, C/EBP alpha
, CAAT/enhancer-binding protein DNA-binding protein
, CAAT/enhancer-binding protein, DNA-binding protein
, CCAAT/enhancer binding protein, alpha
, c/EBP alpha
, CCAAT/enhancer binding protein alpha